Geeta Lalchandani Lalwani, MD
Ophthalmology · Boulder, CONPI 1609891811
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $229,562 of the $319,350 with a category attached, or 71.9%. 21 manufacturers reported payments, led by Novartis at 27.2% of the total. Reporting peaked in 2019 at $92,052 and has fallen 72.9% since, to $24,925 in 2025. Among ophthalmology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 365 payments — averaging $874.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$87K
- Astellas Pharma US Inc$72K
- Genentech USA, Inc.$67K
- Apellis Pharmaceuticals, Inc.$33K
- Regeneron Healthcare Solutions, Inc.$28K
- Genentech, Inc.$16K
- plus $15K from 15 others
Across 7 payments — averaging $2183.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$15K
What the payments were for
- Consulting fees$53,27117%
- Speaking & faculty fees$229,56272%
- Travel & lodging$26,2268%
- Food & beverage$10,2713%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 57 | $86,728 |
| Astellas Pharma US Inc | 71 | $72,470 |
| Genentech USA, Inc. | 71 | $66,674 |
| Apellis Pharmaceuticals, Inc. | 37 | $33,378 |
| Regeneron Healthcare Solutions, Inc. | 32 | $28,403 |
| Genentech, Inc. | 11 | $16,355 |
| AbbVie(2 entities) | 57 | $7,012 |
| Carl Zeiss Meditec, Inc. | 3 | $4,295 |
| Ocular Therapeutix, Inc. | 1 | $1,500 |
| Alcon | 7 | $1,255 |
| Topcon Healthcare, Inc. | 2 | $275 |
| Eyepoint US, Inc. | 3 | $250 |
| Notal Vision, Inc. | 2 | $220 |
| Mallinckrodt Hospital Products Inc. | 2 | $143 |
| Alimera Sciences, Inc. | 1 | $112 |
| Heidelberg Engineering, Inc. | 1 | $76 |
| Bausch & Lomb Americas Inc. | 1 | $72 |
| Harrow Eye, LLC | 3 | $67 |
| Biogen | 1 | $26 |
| Thea Pharma Inc. | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$319,350 in reported general payments places this provider in the 95th percentile of 262 ophthalmology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 123 | $4,125 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 21 | $2,728 |
| Ofloxacin | 50 | $450 |
| Latanoprost | 71 | $421 |
| Ketorolac Tromethamine | 20 | $356 |
| Timolol Maleate | 20 | $341 |
| Brimonidine Tartrate | 17 | $250 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Boulder
- Mark PackerBoulder$3.5M
- Richard StewartBoulder$5K
- Jon DishlerGreenwood Village$1M
- Mark DaceyDenver$370K
- Cristos IfantidesDenver$343K
- Richard DavidsonAurora$316K
- Steven DeweyColorado Springs$246K
- Jack ZamoraDenver$172K
- Eva KimDenver$95K
- Michael JansenDenver$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.